Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of intensified peri-operative doxorubicin and ifosfamide in high-risk CINSARC resectable soft-tissue sarcoma
2018-000186-36Phase 3Active
- Sponsor
- Institut Bergonié
- Start
- Jul 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin and ifosfamide in soft tissue sarcoma (STS) (2 arms), sponsored by Institut Bergonié. Primary endpoint: Metastatic progression-free survival. Started Jul 2018; status: active.
02
Drugs
doxorubicinifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2018-000186-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000186-36.